<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764270</url>
  </required_header>
  <id_info>
    <org_study_id>AT002034-2 (7187)</org_study_id>
    <secondary_id>5P01AT002034</secondary_id>
    <nct_id>NCT00764270</nct_id>
  </id_info>
  <brief_title>The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease</brief_title>
  <official_title>The Role of R-alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to
      reduce risk factors in people with documented heart disease and increased levels of
      inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover study in which participants are randomly assigned to the sequence of receiving R-Alpha Lipoic Acid and Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>12,20 &amp; 32 weeks</time_frame>
    <description>High sensitive C-reactive protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>8-lso-PGF2a</measure>
    <time_frame>12, 20 &amp; 32 weeks</time_frame>
    <description>8-iso-prostaglandin F2alpha</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Lipoic acid treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants take lipoic acid with a washout period before or after placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants take placebo with a washout period before or after lipoic acid treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>R-alpha lipoic acid</intervention_name>
    <description>300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks</description>
    <arm_group_label>Lipoic acid treatment</arm_group_label>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented congestive heart disease (CHD)(defined as at least one significant coronary
             stenosis &gt; 50% on angiography, or history of documented myocardial infarction)

          -  Not diagnosed with unstable angina, uncontrolled hypertension, heart failure, recent
             myocardial infarction (within last six months)

          -  Not taking insulin or oral hypoglycemic agents, anti-inflammatory drugs other than
             aspirin, or hormone replacement therapy

          -  On stable doses for four weeks prior to entry of lipid-lowering therapy (statins),
             aspirin, and angiotensin-converting enzyme inhibitors or other blood pressure
             medications. P

          -  No tobacco use within 3 months of the study

          -  No laboratory evidence of renal, hepatic, or hematological abnormalities

          -  Not currently taking vitamin or antioxidant supplements, including R-alpha lipoic
             acid, except standard multivitamin/mineral supplements containing not more than the
             Daily Value (DV) of the vitamins and minerals;

          -  Elevated levels of urinary and plasma F2-isoprostanes

          -  Elevated plasma levels of hs-CRP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Bobe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon State University</investigator_affiliation>
    <investigator_full_name>Gerd Bobe</investigator_full_name>
    <investigator_title>Principal Investigator, Linus Pauling Institute Associate Professor, Department of Animal and Rangeland Sciences</investigator_title>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>lipoic acid</keyword>
  <keyword>thioctic acid</keyword>
  <keyword>triglycerides</keyword>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

